0A6I Stock Overview
A late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Soligenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.87 |
| 52 Week High | US$14.60 |
| 52 Week Low | US$1.80 |
| Beta | 2.07 |
| 1 Month Change | -11.61% |
| 3 Month Change | -18.27% |
| 1 Year Change | -67.62% |
| 3 Year Change | -98.63% |
| 5 Year Change | n/a |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A6I | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.3% | -0.9% | 0.1% |
| 1Y | -67.6% | -15.4% | 2.3% |
Return vs Industry: 0A6I underperformed the UK Biotechs industry which returned -15.4% over the past year.
Return vs Market: 0A6I underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
| 0A6I volatility | |
|---|---|
| 0A6I Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 0A6I's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 15 | Christopher Schaber | www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.
Soligenix, Inc. Fundamentals Summary
| 0A6I fundamental statistics | |
|---|---|
| Market cap | US$5.91m |
| Earnings (TTM) | -US$9.59m |
| Revenue (TTM) | US$2.34k |
Is 0A6I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A6I income statement (TTM) | |
|---|---|
| Revenue | US$2.34k |
| Cost of Revenue | US$2.34k |
| Gross Profit | US$0 |
| Other Expenses | US$9.59m |
| Earnings | -US$9.59m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.94 |
| Gross Margin | 0% |
| Net Profit Margin | -409,394.19% |
| Debt/Equity Ratio | 0% |
How did 0A6I perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 03:09 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Soligenix, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Brean Capital |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Keith Markey | Griffin Securities |